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A B S T R A C T
Background: Pulmonary vein isolation (PVI) has become an accepted therapy for patients with atrial
ﬁbrillation (AF) and the indications have widened to include non-paroxysmal AF-patients. Maintenance
of sinus rhythm after PVI can be adversely affected by clinical or echocardiographic parameters, which
should be clearly identiﬁed.
Methods and results: After baseline clinical and echocardiographic evaluations, PVI was performed in
patients with paroxysmal or non-paroxysmal AF. The follow-up strategy after PVI included: (1) clinical
follow up, 12-lead electrocardiography (ECG) and 24-h ECG every 3 months, (2) trans-telephonic ECGs
twice daily and when symptomatic (over 4 weeks) every 3 months, or (3) continuous monitoring via
implanted devices. A recurrence was an atrial arrhythmia lasting >30 s. All 340 PVI procedures of 229
patients were analyzed. On average, 1.5 PVI procedures per patient (range, 1–6 PVI) were performed. The
mean age was 58  11 years (73% male) with 109 paroxysmal and 120 non-paroxysmal AF cases. Clinical
follow-up with 12-lead ECGs, 24-h ECGs, trans-telephonic ECGs, and implanted devices was complete in
100%, 63%, 51%, and 16% of cases, respectively. The overall one-year recurrence rate of 59% (range, 24–82%)
was dependent on grades of diastolic function (normal – dysfunction grade III) in a multivariable analysis
model. Patients with normal diastolic function had the lowest recurrence rates of 24% and 49% after 1 and
3 years of follow-up, respectively (p < 0.0001).
Conclusion: Diastolic function could serve as a simple summary predictor for AF recurrence, and would
facilitate clinical decision-making in AF treatment.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The prevalence of atrial ﬁbrillation (AF) in the population is
increasing [1]. In addition to advanced age, hypertension is a well-
known risk factor for AF and has been shown to be predictive for
the development of AF in large population studies [2]. But AF is a
more complex phenomenon associated with electrical, contractile,
and structural changes [3]. The latter can lead to impairment of left
ventricular ﬁlling, which is often reﬂected by diastolic dysfunction
[4]. Diastolic dysfunction and AF share many common risk factors,
including aging and hypertension [5,6]. Hypertension together
with the subsequent development of left ventricular hypertrophy* Corresponding author at: Cardiology Department, Medical University of Vienna,
Wa¨hringer Gu¨rtel 18-20, 1090 Vienna, Austria. Tel.: +43 1 40400 4614;
fax: +43 1 40400 4614.
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsis a well-known risk factor for diastolic dysfunction [7]. Diastolic
dysfunction and AF increase with age [8] and patients with
diastolic dysfunction are more likely to have AF at the time of
diagnosis [9]. One short-term study has suggested that the degree
of diastolic dysfunction correlates with the development of AF [10].
Pulmonary vein isolation (PVI) has become an accepted therapy
for patients with drug-refractory AF and the indications have
broadened to include non-paroxysmal AF patients. However,
recently published long-term studies showed high recurrence
rates up to 70% after a single PVI [11–14]. At present, studies with
long-term follow-up examining the relationship between the
degree of diastolic dysfunction and AF-recurrences are lacking. For
the time being it is unknown whether grading of diastolic function
is relevant for therapeutic decision-making in AF patients.
Therefore, the aim of our study was to assess whether echocardio-
graphic parameters and clinical parameters such as age, hyper-
tension, or history of AF may predict the outcomes of PVI in a
multivariate risk model. reserved.
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Study design and study population
This was a retrospective abstraction of data collected at the
Medical University of Vienna, Department of Cardiology, in
consecutive patients scheduled to undergo PVI. The diagnosis of
paroxysmal, persistent or longstanding persistent AF was estab-
lished using current guidelines [15]. All patients gave their written
permission before PVI after informed consent was obtained. The
local ethics committee approved this study. Inclusion criteria:
symptomatic or clinically intractable AF refractory or intolerant to
at least one Class I or III antiarrhythmic drug. Exclusion criteria:
contraindications to anticoagulation, presence of a left atrial (LA)
thrombus, life expectancy <1 year, overt thyroid dysfunction.
Patients with implanted devices such as pacemakers or deﬁbrilla-
tors, and patients with non-normal left ventricular function or
valvular heart disease were not excluded from PVI.
Echocardiography
Echocardiographic examinations following a standard protocol
[16] were conducted using a Vivid 7 ultrasound machine (GE
Healthcare, Milwaukee, WI, USA) or an ACUSON Sequia C2561
(Acuson, Mountain View, CA, USA) usually in a 3-month window
before PVI. Following the practice at our institution cardioversion
was attempted in all patients prior to ablation. This time window,
when the patient was in sinus rhythm, was used for echocardio-
graphic examinations. Interventricular septal thickness was
obtained at end-diastole from two-dimensional directed M-mode
in the parasternal long axis, according to American Society of
Echocardiography guidelines [17]. Two-dimensional apical 4- and
2-chamber views were used to calculate left ventricular ejection
fraction (LVEF) using the biplane Simpson method. An LVEF <55%
was considered abnormal. The severity of mitral regurgitation was
evaluated semi-quantitatively from the area of the regurgitant jet
by color Doppler. LA antero-posterior diameter in parasternal long-
axis view and LA major axis in apical 4-chamber view were used to
calculate LA diameters.
Grading of diastolic function
Doppler measures of diastolic function were performed
according to recommendations [16] and averaged over three
cardiac cycles in sinus rhythm only. Trans-mitral pulsed-wave
Doppler velocities were recorded at rest and during Valsalva
manoeuver from an apical 4-chamber view with a Doppler sample
of 2 mm placed between the tips of the mitral leaﬂets. Diastolic
function was graded blinded to baseline data or outcomes as
normal, impaired relaxation (grade I), pseudo-normal pattern
(grade II), or as restrictive pattern (grade III), using ofﬂine Doppler
measurements of the mitral inﬂow, mitral inﬂow during Valsalva
manoeuver, and tissue Doppler imaging of the mitral annulus.
Valsalva manoeuver and E/E0 ratio were used to distinguish
between normal and pseudo-normal ﬁlling pattern. For a normal
pattern, the reference ranges used were as follows: ratio of early (E)
to late (A) diastolic ﬁlling velocities in the mitral inﬂow recording
between 1 and 2; deceleration time (DT) of early ﬁlling between
150 ms and 220 ms; ratio of systolic to diastolic peak velocity
mitral E/A ratio during Valsalva manoeuver >1 with a reduction
compared to baseline of <0.5 of the absolute ratio. Grade I diastolic
dysfunction was consistent with an E/A ratio <1, DT >220 ms, and
no substantial change in E/A ratio during Valsalva. Grade II diastolic
dysfunction resembled the normal conﬁguration with respect to
the mitral inﬂow but with 2 of the following features: mitral E/A
ratio <1 during Valsalva manoeuver with a reduction of at least0.5 of the absolute ratio, and E/E0 ratio by tissue Doppler imaging of
>15 [18]. Grade III diastolic dysfunction was characterized by an E/
A ratio of >2, a DT <150, and E/E0 >15.
Ablation procedure
All patients underwent either cardiac computer tomography
and/or trans-esophageal echocardiography just prior to the
procedure to exclude left atrial thrombi and to acquire left atrial
anatomy. After obtaining vascular access from the left femoral
vein, one decapolar steerable diagnostic catheter was positioned in
the coronary sinus (6 Fr, Dynamic Deca, C.R. Bard, Inc., Lowell, MA,
USA). Deep sedation was initiated with intravenous midazolam
and propofol. Intravenous heparin was administered to maintain
an activated clotting time at 300 s. PVI was performed using either
conventionally hand-held system or with the use of a magnetic
navigation system (MNS) depending on the interventionist’s
preference. PVI study techniques and system functions have been
described in detail elsewhere [19,20] and were adapted based on
the operator’s decision. Brieﬂy, in MNS patients one ﬂuoroscopi-
cally guided transseptal puncture was performed to position
one sheath within the left atrium (SRO, 8.5 Fr and BRKTM
Transseptal Needle, St. Jude Medical, Inc., St. Paul, MN, USA). In
the conventional group two ﬂuoroscopically guided transseptal
punctures were performed to position two sheaths within the left
atrium. Left atrial mapping was performed with a NAVISTAR1
ThermocoolTM, 3.5 mm, open-irrigated tip (Biosense Webster,
Inc., Diamond Bar, CA, USA) or in MNS patients with a
NAVISTAR1 RMT DS, 8 mm tip or 3.5-mm-tip (the latter is
open-irrigated, Biosense Webster). In the conventional group a
multipole circular catheter (Lasso 15 or 20 mm, Biosense
Webster) was used to guide ablation in order to achieve PVI
conﬁrmed by entrance block (coronary sinus pacing for the left-
sided PVs). Maps were compared with preprocedure computed
tomographic images (CartomergeTM, Biosense Webster). Wide
area circumferential ablation was performed and lesions were
placed in a point-by-point fashion (MNS group, 40 W, tempera-
ture limit 45 8C, 15 s) or linear fashion (conventional group,
40 W, temperature limit 45 8C). After wide area circumferential
ablation in the MNS group, the roving catheter was used to guide
additional ablation at the tubular portion of each PV to achieve
segmental PVI in 108 increments of catheter movement [19]. PV
entrance block was conﬁrmed by abolition of PV potentials
conﬁrmed with 32-fold threshold ampliﬁcation on the EP
Recording System (coronary sinus pacing for the left-sided
PVs). Overall, the procedural end point in both groups was
achievement of PV entrance and exit block.
Post-ablation management and monitoring
The recommended initial follow-up was to see all the patients
at 1, 3, 6, 9, and 12 months post-ablation at the outpatient
department. If patients did not have an implanted device capable
of loop monitoring, patients were asked to employ event recorders
post PVI at weeks 1–4, 13–16, 25–28, and 37–40 and to send an
ECG at least twice a day and additionally when they felt any
discomfort. Twenty-four-hour ECG recordings post-PVI at week 5,
17, 29, 41, and 52 were recommended. After 52 weeks, additional
ECG recordings at 3-month intervals were requested, if non-
sustained AF/ﬂutter/tachycardia had been previously detected or
the patient was symptomatic.
Endpoints
Endpoints for both groups were single patient success. Success
was deﬁned as freedom from AF/ﬂutter/tachycardia. After the
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tachycardia lasting for 30 s or more was considered a recurrence.
Statistical analysis
Mean  standard deviation is shown for metric variables and
absolute frequencies (relative frequencies within a column) for
categorical variables. Mean differences in metric variables between
the categories were assessed by one-way ANOVA or, if the
assumptions were not met, by the Kruskal–Wallis test. Equality of
the distribution of categorical variables between categories was
assessed by a Chi-square test of independence or, if any expected
number of observations was below 5 and one variable had only two
categories assessment would be made using Fisher’s exact test.
Time-to-event distributions were estimated by the Kaplan–Meier
method separately for each instance of recurrence. Kaplan–Meier
curves were compared using the log-rank test. To include the time-
to-event information from all recurrent events of each patient,
conditional gap time models according to Prentice, Williams, and
Peterson were calculated [21]. Common effects were assumed,
meaning that the effect of a given predictor variable on the hazard
rate is identical in each instance of recurrence. This assumption is
justiﬁed by the observation of highly similar time-to-event
distribution estimates for each recurrence. Simple Cox models
were calculated initially to regress the time-to-event on each
covariate separately. A multiple model was then selected from the
scope of variables that were signiﬁcant on a level of 0.05 in
the simple models. A stepwise selection procedure was used with
the signiﬁcance limit to enter the model set to 0.15 and the limit toTable 1
Clinical and echocardiographic data and stratiﬁcation according to diastolic (dys)funct
No. of patients Total (n = 229) Normal (n = 57) 
Baseline characteristics
Age (years) 58  11 54  12 
Male (n) 167 (73%) 35 (61%) 
Body mass index 28  5 26  4 
History of atrial ﬁbrillation 
Paroxysmal 109 (48%) 32 (56%) 
Persistent 85 (37%) 23 (40%) 
Long-standing persistent 35 (15%) 2 (4%) 
Comorbidities
Hypertension 186 (81%) 37 (65%) 
Coronary artery disease 26 (11%) 1 (2%) 
Diabetes 17 (7%) 2 (4%) 
History of ischemic attack 16 (7%) 1 (2%) 
COPD 11 (5%) 2 (4%) 
Hyperlipidemia 53 (23%) 6 (11%) 
Kidney dysfunction 5 (2%) 1 (2%) 
Echocardiographic parameters
Ejection fraction 
Normal LVEF 203 (89%) 56 (98%) 
Mild LVEF reduction 20 (9%) 1 (2%) 
Moderate LVEF reduction 5 (2%) 0 (0%) 
Severe LVEF reduction 1 (0%) 0 (0%) 
Valves 
Moderate to severe valve disease 17 (8%) 5 (10%) 
No mitral regurgitation 99 (46%) 32 (64%) 
Mild mitral regurgitation 71 (33%) 12 (24%) 
Moderate mitral regurgitation 39 (18%) 6 (12%) 
Severe mitral regurgitation 5 (2%) 0 (0%) 
Left atrium 16 (7%) 1 (2%) 
A.p. parasternal long-axis view 45.9  6.3 42.7  5.9 
Normal = 28–40 mm 25 (19%) 9 (39%) 
Mild enlarged = 41–46 mm 50 (38%) 8 (35%) 
Moderate enlarged = 47–52 mm 39 (30%) 5 (22%) 
Severe enlarged > 52 mm 17 (13%) 1 (4%) 
Interventricular septum (mm) 12.6  1.8 11.3  1.5 
aov, one-way ANOVA; chisq, Chi-square test; f, Fisher’s exact test; COPD, chronic obstay in the model set to 0.05. Software: SAS1 Version 9.3 (SAS Inst.,
Cary, NC, USA).
Results
This study included baseline data of 229 patients with follow-
ups of 340 PVI procedures (73% males; median age, 59 years, range,
30–80 years) undergoing radiofrequency ablation for drug-
refractory symptomatic paroxysmal (48%), persistent (37%), or
longstanding persistent (15%) AF. Patients’ clinical characteristics
are summarized in Table 1. The most frequent comorbidity was
hypertension (81%) followed by hyperlipidemia (23%). Only 2% of
patients had more than a mild reduction in left ventricular ejection
fraction and 8% had valvular heart disease other than mitral
regurgitation. Nineteen percent of all patients had normal left
atrial diameters, whereas moderate to severe left atrial enlarge-
ment was present in 43% of cases.
PVI and follow-up data
The number of repeated PVIs performed and the rates of
procedural success for index and repeated PVIs are shown in
Fig. 1. Not all patients with recurrences consented to a ‘‘re-do’’
procedure due to improvement in symptoms. PVI was performed
manually and with MNS in 233 (68%) and 107 (32%) cases,
respectively. The mean overall follow-up time was 1.7  1.4 years
per PVI procedure. Clinical follow-up with 12-lead ECGs, 24-h
recordings, trans-telephonic ECGs, and implanted monitoring devices
were available in 100%, 63%, 51%, and 16% of cases, respectively.ion.
Grade I (n = 87) Grade II (n = 46) Grade III (n = 39) p for trend
59  10 59  12 62  10 0.0013 aov
66 (76%) 37 (80%) 29 (74%) 0.1347 f
28  4 29  5 29  5 0.0039 aov
0.0019 chisq
44 (51%) 16 (35%) 17 (44%)
31 (36%) 14 (30%) 17 (44%)
12 (14%) 16 (35%) 5 (13%)
75 (86%) 41 (89%) 33 (85%) 0.0036 f
11 (13%) 4 (9%) 10 (26%) 0.0029 f
5 (6%) 2 (4%) 8 (21%) 0.0198 f
7 (8%) 4 (9%) 4 (10%) 0.2636 f
6 (7%) 2 (4%) 1 (3%) 0.7795 f
25 (29%) 11 (24%) 11 (28%) 0.0656 f
1 (1%) 0 (0%) 3 (8%) 0.0967 f
0.003 f
78 (90%) 39 (85%) 30 (77%)
6 (7%) 6 (13%) 7 (18%)
2 (2%) 1 (2%) 2 (5%)
1 (1%) 0 (0%) 0 (0%)
0.0071 f
3 (4%) 1 (2%) 8 (21%)
39 (48%) 17 (39%) 11 (28%) 0.0056 chisq
26 (32%) 15 (34%) 18 (46%)
16 (20%) 11 (25%) 6 (15%)
0 (0%) 1 (2%) 4 (10%)
7 (8%) 4 (9%) 4 (10%) 0.2636 f
45.6  5.2 46  6.4 49.3  7.3 0.0004 aov
6 (11%) 8 (29%) 2 (8%)
27 (49%) 6 (21%) 9 (36%)
17 (31%) 10 (36%) 7 (28%)
5 (9%) 4 (14%) 7 (28%) 0.0086 f
12.9  1.8 12.9  1.6 13.5  1.7 <0.0001 aov
structive pulmonary disease; LVEF, left ventricular ejection fraction.
Fig. 3. Sucess rates regarding history of AF. Kaplan–Meier curve of the long-term
freedom from recurrence after ablation excluding a 2-month post-procedural
blanking window in case the remaining follow-up was event-free. Stratiﬁcation
according to history of atrial ﬁbrillation [0 = paroxysmal (PAR), 1 = persistent (PER),
2 = long-standing persistent (LPER)]: patients with long-standing persistent atrial
ﬁbrillation had the highest recurrence rate (p = 0.0043).
Fig. 1. Procedural ﬂow-chart. Outcomes of 340 PVI procedures in 229 patients.
Number of repeated PVIs performed and rates of procedural success for repeated
PVIs. The one patient with six PVI procedures is not shown. The mean overall
follow-up time with complete follow-up electrocardiograms was 1.7  1.4 years per
PVI procedure. PVI, pulmonary vein isolation.
Fig. 2. Time-to-recurrence distribution. Kaplan–Meier estimate for the long-term
freedom from recurrence after ablation excluding a 2-month post-procedural
blanking window in case the remaining follow-up was event-free. Stratiﬁcation
according to index procedure (PVI 1) and re-do procedures (PVI 2–4). There was no
signiﬁcant difference regarding time-to-recurrence (p = 0.8236). PVI, pulmonary
vein isolation.
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Fig. 2 demonstrates that the time to a recurrence was not different
regarding index or re-do PVI procedures (p = 0.8236). PVI success
according to AF history is shown in Fig. 3: there was a signiﬁcantly
worse outcome in patients with longstanding persistent AF
(p = 0.0043).Table 2
Medication and PVI outcome data stratiﬁcation according to diastolic (dys)function.
Nr. of patients Total (n = 229) Normal (n = 57) Gra
Medication (index PVI)
No AA Class I/III 112 (49%) 35 (61%) 
AA Class I 25 (11%) 7 (12%) 
AA Class II 139 (61%) 37 (65%) 
AA Class III 80 (35%) 13 (23%) 
AA Class IV 27 (12%) 3 (5%) 
Diuretics 49 (21%) 9 (16%) 
Phenprocoumon 166 (72%) 29 (51%) 
Digitalis 5 (2%) 0 (0%) 
Statins 57 (25%) 12 (21%) 
ACE 54 (23%) 14 (25%) 
ARB 47 (21%) 6 (11%) 
PVI outcomes
PVI procedures/per patient 340/1.5 65/1.1 
PVI recurrence rate (1 year) 128 (59%) 12 (24%) 
chisq, Chi-square test; f, Fisher’s exact test; PVI, pulmonary vein isolation; AA, anti-arrh
blocker.Simple, univariable and selected, multivariable Cox model for PVI
success
The potential baseline predictor variables considered in simple-
univariable conditional gap time Cox models are outlined inde I (n = 87) Grade II (n = 46) Grade III (n = 39) p for trend
45 (52%) 23 (50%) 9 (23%) 0.0026 f
10 (11%) 3 (7%) 5 (13%) 0.7543 f
53 (61%) 24 (52%) 25 (64%) 0.5689 f
29 (33%) 18 (39%) 20 (51%) 0.0331 f
11 (13%) 8 (17%) 5 (13%) 0.2517 f
19 (22%) 7 (15%) 14 (36%) 0.072 f
63 (72%) 38 (83%) 36 (92%) <0.0001 f
1 (1%) 2 (4%) 2 (5%) 0.1656 f
23 (26%) 11 (24%) 11 (28%) 0.8463 f
19 (21%) 8 (17%) 13 (33%) 0.3599 chisq
20 (23%) 11 (24%) 10 (26%) 0.1897 f
122/1.4 78/1.7 79/2.0 0.0031 f
46 (52%) 38 (77%) 32 (82%) <0.0001 f
ythmic; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
Table 3a
Simple, univariate Cox model for all PVI procedures regarding recurrence.
Parameter p value Hazard ratio 95% CI lower 95% CI upper Global p-value
Baseline characteristics
Age (years) 0.5672 1.004 0.991 1.017
Gender 0.1541 0.779 0.552 1.098
Body mass index 0.0711 1.028 0.998 1.060
Paroxysmal AF 1 0.022
Persistent AF 0.3056 1.180 0.860 1.620
Long-standing persistent AF 0.0058 1.729 1.172 2.552
Comorbidities
Hypertension 0.0188 1.580 1.079 2.314
Coronary artery disease 0.6541 1.112 0.698 1.773
Diabetes 0.3208 1.322 0.762 2.292
History of ischemic attack 0.4738 1.241 0.688 2.240
COPD 0.7781 1.115 0.522 2.385
Hyperlipidemia 0.7474 1.059 0.747 1.501
Kidney dysfunction 0.1586 1.906 0.778 4.671
Echocardiographic parameters
LVEF 0.1257 1.270 0.935 1.725
Moderate to severe valve disease 0.0112 1.788 1.141 2.800
Mitral regurgitation 0.0427 1.214 1.006 1.466
Normal diastolic function 1 <0.0001
Diastolic dysfunction I 0.0002 3.088 1.721 5.540
Diastolic dysfunction II <0001 5.407 2.958 9.884
Diastolic dysfunction III <0001 6.876 3.764 12.560
Left atrial diameter 0.0062 1.038 1.011 1.067
Interventricular septum 0.0137 1.102 1.020 1.191
Non-baseline
Success and no magnetic navigation system PVI 1 0.157
Magnetic navigation system PVI 0.0722 1.395 0.970 2.006
Hand-held PVI 0.263 1.241 0.850 1.813
Table 3b
Selected, multivariate Cox model for all PVI procedures regarding recurrence.
Parameter Parameter estimates Std. error p value Hazard ratio 95% CI lower 95% CI upper
Normal diastolic function 0 1
Diastolic dysfunction I 0.984 0.300 0.0011 2.675 1.485 4.82
Diastolic dysfunction II 1.597 0.310 <0.0001 4.94 2.692 9.065
Diastolic dysfunction III 1.741 0.308 <0.0001 5.701 3.115 10.436
Moderate to severe valve disease 0.544 0.238 0.0219 1.723 1.082 2.745
PVI, pulmonary vein isolation; AF, atrial ﬁbrillation; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction.
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non-paroxysmal AF, hypertension, moderate to severe valve
disease, mitral regurgitation, diastolic (dys)function, left atrial
diameter, and interventricular septum thickness were identiﬁed to
be signiﬁcant predictors of recurrences in the simple models, i.e.
when no other potential predictors were accounted for (Table 3a).
Overall, no signiﬁcant impact on recurrence was found regarding
the method used for PVI (manually vs. MNS, p = 0.157) (Table 3a).
In the resulting multivariable model, diastolic dysfunction and
moderate to severe valve disease remained signiﬁcant in predict-
ing recurrences (Table 3b). When compared to normal diastolic
function, diastolic dysfunction grade I resulted in a hazard ratio of
2.7 (CI: 1.5–4.8) and diastolic dysfunction grade II and grade III
had ratios of 4.9 (CI: 2.7–9.1) and 5.7 (CI: 3.1–10.4), respectively
(Table 3b).
The association between the occurrence of PV-reconnections and
AF-recurrences was found to be low for the 2nd PVI. In total, 34
patients had one PV, 33 patients had two PVs, eight patients had
three PVs, and one patient had all four PVs reconnected. For each PV
(left superior PV, left inferior PV, right superior PV, right inferior PV
or all PVs), 32 out of 76 patients had re-connections; however, they
were not the same patients and no clear correlation between
different PVs was observed. There was a borderline signiﬁcant trend
toward an increased risk for an additional (3rd) PVI with right
inferior PV (p = 0.034). However, when accounting for multipletesting for all PVs, it is not possible to conclude that any of the PV-
reconnections has a pronounced effect on the outcome.
Differences based on diastolic function grading
Fifty-seven patients (25%) presented with normal diastolic
function, whereas grade I, grade II, and grade III diastolic
dysfunction were present in 38%, 20%, and 17%, respectively
(Table 1). Echocardiography was done in sinus rhythm in a
3-month interval before PVI. In 5.3%, 4.6%, 4.3%, and 5.1% of cases,
respectively, echocardiography was done on the day of electrical
cardioversion. In all other patients the median time between
cardioversion and echocardiographic investigation in sinus rhythm
was 11.7 days (range 3.2–18.4 days). Patients with a higher grade
of diastolic dysfunction were older (p = 0.0013) and had a higher
body mass index (p = 0.0039). Comorbidities such as hypertension,
coronary artery disease, and diabetes were signiﬁcant more
frequently observed in patients with diastolic dysfunction.
Impairment of systolic dysfunction was associated with diastolic
dysfunction (p = 0.003). The same was true for moderate to severe
valvular heart disease. Patients with normal diastolic function had
signiﬁcantly smaller left atrial diameters compared to patients
with diastolic dysfunction (p = 0.0004) (Table 1). Differences
regarding antiarrhythmic drug treatment after index PVI and
PVI outcomes are outlined in Table 2: higher rates of PVI
Fig. 4. Sucess rates regarding diastolic function. Kaplan–Meier curve of the long-
term freedom from recurrence after ablation excluding a 2-months post-procedural
blanking window in case the remaining follow-up was event-free. Stratiﬁcation
according diastolic (dys)function (DIA_N = normal, DIA_I = grade I, DIA_II = grade II,
DIA_III = grade III). The patients with normal diastolic function had the best
outcome with recurrence rates of 24% and 49% after 1 and 3 years of follow-up,
respectively (p < 0.0001).
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correlated signiﬁcantly with the presence and severity of diastolic
dysfunction. Patients with normal diastolic function had the
lowest recurrence rates of 24% after 1 and 2 years of follow-up,
respectively (p < 0.0001) (Fig. 4).
Discussion
This study population represents a well-characterized sample
of real-life patients undergoing PVI for symptomatic, drug
refractory, and clinically intractable AF. The major ﬁnding of this
study is that diastolic function could serve as a simple summary
predictor for AF recurrence, and would facilitate clinical decision-
making in patients with paroxysmal and non-paroxysmal AF
scheduled for PVI.
Identiﬁcation of baseline clinical and echocardiographic pre-
dictors of success in maintaining sinus rhythm after PVI is crucial in
contemporary AF treatment [22]. Besides advanced age and
hypertension [2] enlarged left atrial diameters are a well-known
risk factor for AF [23]. Elderly or hypertensive patients have stiffened
left ventricles (LVs) that give rise to elevated LA pressure and LA
enlargement, the conditions predisposing to AF [24]. Ventricular
diastolic dysfunction might underlie the effect of hypertension on LA
dynamics, but this relationship is still speculative, multifactorial,
and difﬁcult to reverse [25]. The important role of diastolic function
in promoting and perpetuating AF is well established [10]. Current
guidelines state that LV systolic and diastolic performance help in
decision-making regarding antiarrhythmic and antithrombotic drug
therapies only [26]. There are no speciﬁc recommendations for the
management of invasive catheter procedures in patients stratiﬁed
according to their diastolic function. The presence and severity of
diastolic dysfunction are independently predictive of ﬁrst docu-
mented AF in the elderly [10]; however, there are only limited data
[27–33] available demonstrating an association between the
presence of diastolic dysfunction and PVI outcomes. To date, it is
uncertain whether AF patients with different grades of diastolic
dysfunction should be treated the same.
Diastolic dysfunction is reported to be an independent
predictor in lone AF, new onset AF, and transition to chronic AF
in patients with paroxysmal AF [10]. Li et al. [27] reported the
association between diastolic function and AF recurrence after PVI,
however, the follow-up period was short (3 months). A study with
a longer follow-up period was published by Ejima et al. [28]: only
36% in a sample of 80 patients had diastolic dysfunction, but they
had the worst outcome after PVI. Similar to our study LA diameter
was not an independent predictor of AF recurrence after PVI. Weare in line with others [29–32] who reported that diastolic
dysfunction and/or LA stiffness index were independent predictors
of recurrence after PVI. To our knowledge, the only available long-
term study where a detailed grading of diastolic dysfunction was
performed is the study of Cha et al. [33]. Most of their patients had
grade II diastolic dysfunction, which is in contrast to our study
where most of the patients presented with grade I diastolic
dysfunction. We agree with the conclusion of Cha et al., who
demonstrated that AF ablation in patients with diastolic dysfunc-
tion is not efﬁcacious in the long-term.
This study population represents a selected group of patients
compared to data from community-based surveys: our study
patients were younger (58  11 years vs. 74.2  11 years) and had a
different history of AF (37% persistent, 15% long-standing persistent
vs. 7% persistent, 47% long-standing persistent) compared to the
Fushimi AF registry [34]. This might explain the clearly demonstrated
lower efﬁciency of ablation in patients with impaired diastolic
function. This lower efﬁciency might become less evident when
applying to the older Fushimi AF patients with a mean age of 74.2
years. Otherwise, in the study of Lee et al. [35] a clear relation
between LA mechanical function and the degree of LA remodeling and
LV diastolic function was found and the contribution of LV diastolic
dysfunction to LA electro-anatomical remodeling was especially
signiﬁcant in older patients with large LA diameters.
A better stratiﬁcation of AF patients who beneﬁt most from PVI
should be mandatory since two recent studies report on less
favorable PVI results: the FAST-trial showed that the more invasive
surgical ablation is superior to catheter ablation in achieving
freedom from LA arrhythmias in patients with dilated left atrium
and hypertension [36]. In comparing PVI with antiarrhythmic drug
therapy as ﬁrst-line treatment in patients with paroxysmal AF, no
difference between the treatment groups was found by Cosedis
Nielsen et al. [37]. As a consequence our data support the view that
pre-procedural echocardiographic LA and ventricular diastolic
parameters should be obtained in patients scheduled for PVI in
order to predict outcome.
In AF ablation the reported success rate very much depends
upon the monitoring technique applied. Piorkowski et al. [38]
reported on success rates after PVI with the use of different
monitoring strategies: 70% freedom from AF on a symptom-only-
based follow-up, 50% on serial 7-day ECG, and only 45% on trans-
telephonic monitoring. Sorgente et al. [13] reported about 2/3 of AF
relapses occurring in the ﬁrst year of follow-up after PVI. In the
present study, a close meshed monitoring system with 12-lead
ECGs and clinical follow-up, 24-h ECGs, trans-telephonic ECGs and
continuous monitoring via implanted devices was completed in
100%, 63%, 51%, and 16% of cases, respectively. In the light of the
above-mentioned differences in the success rate depending upon
the (monitoring) technique used, our results compare well with
those previously reported by others [13].
Limitations
The present single-center, retrospective study had limitations.
First, it cannot be ruled out that AF treatment is limited by the
ability to record all asymptomatic episodes of AF. Therefore, our
ﬁndings may have overestimated the efﬁcacy of ablation. Second,
diastolic function should be graded in sinus rhythm. The
retrospective study design is more a strength than limitation
since it guaranteed that grading of diastolic function was not
inﬂuenced by later PVI outcomes.
Conclusion
The success rate of non-pharmacological interventions to treat
AF depends upon the follow-up strategy applied and upon the
T. Pezawas et al. / Journal of Cardiology 65 (2015) 479–486 485presence or absence of structural changes of the heart. In
unselected patients PVI may be considered a palliative strategy
with high recurrence rates. In this study we could demonstrate
that different grades of diastolic (dys)function directly correlate
with PVI outcome. Diastolic dysfunction is either the most
determining independent risk factor or it efﬁciently encompasses
much of the information contained in well-appreciated risk factors
such as hypertension, advanced age, and LA size. In any case,
diastolic dysfunction may be considered a useful summary
predictor for AF recurrence.
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